氟哌啶醇与齐拉西酮治疗危重症谵妄
该随机、双盲、安慰剂对照试验纳入急性呼吸衰竭或休克合并低活动型或高活动型谵妄的ICU患者,比较静脉氟哌啶醇(最大日剂量20 mg)、齐拉西酮(最大日剂量40 mg)与安慰剂。主要终点为14天干预期间无谵妄或无昏迷的存活天数,三组分别为安慰剂组8.5天(95%CI 5.6-9.9)、氟哌啶醇组7.9天(95%CI 4.4-9.6)、齐拉西酮组8.7天(95%CI 5.9-10.0),总体效应P=0.26。氟哌啶醇或齐拉西酮与安慰剂相比对主要终点无显著影响(OR分别为0.88[95%CI 0.64-1.21]和1.04[95%CI 0.73-1.48])。次要终点及锥体外系症状频率组间无显著差异。
要点
- 在急性呼吸衰竭或休克合并谵妄的ICU患者中,氟哌啶醇组无谵妄或无昏迷存活天数中位数7.9天(95%CI 4.4-9.6),与安慰剂组8.5天(95%CI 5.6-9.9)相比无显著差异(OR 0.88,95%CI 0.64-1.21)。
- 齐拉西酮组无谵妄或无昏迷存活天数中位数8.7天(95%CI 5.9-10.0),与安慰剂组8.5天(95%CI 5.6-9.9)相比无显著差异(OR 1.04,95%CI 0.73-1.48)。
- 三组总体比较无谵妄或无昏迷存活天数无显著差异(P=0.26)。
- 30天和90天生存率、脱离机械通气时间、ICU及医院出院时间等次要终点组间无显著差异。
- 锥体外系症状和过度镇静等安全性终点组间无显著差异。
适用人群与场景
- 纳入ICU中急性呼吸衰竭或休克合并低活动型或高活动型谵妄的患者。
- 谵妄发生率为48%(566/1183),其中低活动型占89%,高活动型占11%。
诊断标准与关键阈值
- 谵妄诊断采用ICU意识模糊评估法(Confusion Assessment Method for the ICU,CAM-ICU)。
处置流程与药物剂量
- 氟哌啶醇:静脉推注,最大日剂量20 mg。
- 齐拉西酮:静脉推注,最大日剂量40 mg。
- 试验药物或安慰剂的剂量和体积根据每12小时评估的谵妄(采用CAM-ICU)及干预副作用情况减半或加倍。
- 中位暴露时间为4天(四分位距3-7天)。
研究设计与关键结果
- 研究类型:随机、双盲、安慰剂对照试验;566例谵妄患者随机分配至安慰剂组184例、氟哌啶醇组192例、齐拉西酮组190例。
- 主要终点(14天干预期间无谵妄或无昏迷的存活天数中位数):安慰剂组8.5天(95%CI 5.6-9.9),氟哌啶醇组7.9天(95%CI 4.4-9.6),齐拉西酮组8.7天(95%CI 5.9-10.0),总体效应P=0.26。
- 氟哌啶醇 vs 安慰剂对主要终点的OR 0.88(95%CI 0.64-1.21);齐拉西酮 vs 安慰剂OR 1.04(95%CI 0.73-1.48),均无显著影响。
- 次要终点(30天和90天生存率、脱离机械通气时间、ICU及医院出院时间)组间无显著差异。
- 安全性:锥体外系症状频率组间无显著差异。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验。
- 资助:美国国立卫生研究院和VA老年研究教育与临床中心;临床试验注册号NCT01211522。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU中急性呼吸衰竭或休克合并低活动型或高活动型谵妄的患者,使用氟哌啶醇或齐拉西酮与安慰剂相比未显著改变无谵妄或无昏迷的存活天数。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There are conflicting data on the effects of antipsychotic medications on delirium in patients in the intensive care unit (ICU).
METHODS: In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), or placebo. The volume and dose of a trial drug or placebo was halved or doubled at 12-hour intervals on the basis of the presence or absence of delirium, as detected with the use of the Confusion Assessment Method for the ICU, and of side effects of the intervention. The primary end point was the number of days alive without delirium or coma during the 14-day intervention period. Secondary end points included 30-day and 90-day survival, time to freedom from mechanical ventilation, and time to ICU and hospital discharge. Safety end points included extrapyramidal symptoms and excessive sedation.
RESULTS: Written informed consent was obtained from 1183 patients or their authorized representatives. Delirium developed in 566 patients (48%), of whom 89% had hypoactive delirium and 11% had hyperactive delirium. Of the 566 patients, 184 were randomly assigned to receive placebo, 192 to receive haloperidol, and 190 to receive ziprasidone. The median duration of exposure to a trial drug or placebo was 4 days (interquartile range, 3 to 7). The median number of days alive without delirium or coma was 8.5 (95% confidence interval [CI], 5.6 to 9.9) in the placebo group, 7.9 (95% CI, 4.4 to 9.6) in the haloperidol group, and 8.7 (95% CI, 5.9 to 10.0) in the ziprasidone group (P=0.26 for overall effect across trial groups). The use of haloperidol or ziprasidone, as compared with placebo, had no significant effect on the primary end point (odds ratios, 0.88 [95% CI, 0.64 to 1.21] and 1.04 [95% CI, 0.73 to 1.48], respectively). There were no significant between-group differences with respect to the secondary end points or the frequency of extrapyramidal symptoms.
CONCLUSIONS: The use of haloperidol or ziprasidone, as compared with placebo, in patients with acute respiratory failure or shock and hypoactive or hyperactive delirium in the ICU did not significantly alter the duration of delirium. (Funded by the National Institutes of Health and the VA Geriatric Research Education and Clinical Center; MIND-USA ClinicalTrials.gov number, NCT01211522 .).
参考来源
- Girard TD, Exline MC, Carson SS, et al. Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. N Engl J Med. 2018. PMID: 30346242. doi:10.1056/NEJMoa1808217
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。